Management of Heart Failure: Messages from Trials Beyond AHA 2022 Guidelines

Abstract

The major takeaway from 2022 Heart Failure guidelines (AHA/ACC/HFSA) was the 4-pillar concept of use of beta-blockers, RAAS inhibition (preferably ARNI), mineralocorticoid antagonist, and SGLT2 inhibitors (irrespective of diabetes) for HFrEF. The recommendations for HFpEF and HF mildly reduced EF are less robust. Some important heart failure trials are presented every year at ACC, AHA, ESC, and TCT, which can impact our practice even before the release of next guidelines. In this review, some select heart failure trials presented at these scientific meetings after January 2022 are briefly discussed with focus on the message they convey.